DGAT-3

DGAT-3 Struktur
701232-20-4
CAS-Nr.
701232-20-4
Englisch Name:
DGAT-3
Synonyma:
DGAT-3;CS-120;T-863;T 863;trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid;trans-Cyclohexaneacetic-acid,-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl];trans-2-(4-(4-(4-aMino-7,7-diMethyl-7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid;Mino-7,7-diMethyl-2-((1r,4r)-4-(4-(4-a7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid;Cyclohexaneacetic acid, 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-, trans-;2-((1,4-trans)-4-(4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)- phenyl)cyclohexyl)acetic acid;Diglyceride acyltransferase,inhibit,acyl-CoA:cholesterol acyltransferase,T 863,T-863,T863,Inhibitor,Acyltransferase,mono- acylglycerol acyltransferase,Diacylglycerol acyltransferase
CBNumber:
CB31872285
Summenformel:
C22H26N4O3
Molgewicht:
394.47
MOL-Datei:
701232-20-4.mol

DGAT-3 Eigenschaften

Siedepunkt:
616.6±55.0 °C(Predicted)
Dichte
1.36±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
Löslichkeit
DMSO: soluble15mg/mL (clear solution)
pka
4.72±0.10(Predicted)
Aggregatzustand
powder
Farbe
white to beige

Sicherheit

WGK Germany  3

DGAT-3 Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

T863 has been used as a diglyceride acyltransferase (DGAT1) inhibitor:
  • to provide the opportunity to precisely control the DGAT inhibition
  • to treat mouse embryonic fibroblasts (MEFs) to analyse lipid droplet biogenesis
  • to specifically block neutral?lipid synthesis?and lipid droplet formation in HT-1080 cells
  • to block lipid droplet (LD) formation

Biochem/physiol Actions

T863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.

DGAT-3 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


DGAT-3 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 61)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32951 60
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63687 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49374 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 32063 58
Career Henan Chemica Co
+86-0371-86658258 +8613203830695
laboratory@coreychem.com China 30241 58
TargetMol Chemicals Inc.

support@targetmol.com United States 38463 58
ShenZhen Trendseen Biological Technology Co.,Ltd.
13417589054
trendseenbio@gmail.com China 11681 58
Aladdin Scientific
+1-+1(833)-552-7181
sales@aladdinsci.com United States 57505 58
Amadis Chemical Company Limited
571-89925085
sales@amadischem.com China 131957 58

701232-20-4()Verwandte Suche:


  • DGAT-3
  • Cyclohexaneacetic acid, 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-, trans-
  • trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid
  • Mino-7,7-diMethyl-2-((1r,4r)-4-(4-(4-a7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid
  • trans-2-(4-(4-(4-aMino-7,7-diMethyl-7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid
  • 2-((1,4-trans)-4-(4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)- phenyl)cyclohexyl)acetic acid
  • T-863;T 863
  • CS-120
  • trans-Cyclohexaneacetic-acid,-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]
  • Diglyceride acyltransferase,inhibit,acyl-CoA:cholesterol acyltransferase,T 863,T-863,T863,Inhibitor,Acyltransferase,mono- acylglycerol acyltransferase,Diacylglycerol acyltransferase
  • 701232-20-4
Copyright 2019 © ChemicalBook. All rights reserved